References
- 1. E. Tanai and S. Frantz, Pathophysiology of heart failure, Compr. Physiol. 6 (2015) 187–214; https://doi.org/10.1002/cphy.c14005510.1002/cphy.c14005526756631
- 2. P. Anversa, P. Li, A. Malhotra, X. Zhang, M. V. Herman and J. M. Capasso, Effects of hypertension and coronary constriction on cardiac function, morphology, and contractile proteins in rats, Am. J. Physiol. 265 (1993) H713-H724; https://doi.org/10.1152/ajpheart.1993.265.2.H71310.1152/ajpheart.1993.265.2.H7138368372
- 3. B. Vulesevic, M. G. Sirois, B. G. Allen, S. D. Denus and M. White, Subclinical inflammation in heart failure: A neutrophil perspective author links open overlay panel, Can. J. Cardiol. 34 (2018) 717–725; https://doi.org/10.1016/j.cjca.2018.01.01810.1016/j.cjca.2018.01.01829801737
- 4. F. Piccirillo, M. Carpenito, G. Verolino, C. Chello, A. Nusca, M. Lusini, C. Spadaccio, F. Nappi, G. D. Sciascio and A. Nenna, Changes of the coronary arteries and cardiac microvasculature with aging: Implications for translational research and clinical practice, Mech. Ageing Dev. 184 (2019) 111161; https://doi.org/10.1016/j.mad.2019.11116110.1016/j.mad.2019.11116131647940
- 5. P. Balakumar, A. P. Singh and M. Singh, Rodent models of heart failure, J. Pharmacol. Toxicol. Meth. 56 (2007) 1–10; https://doi.org/10.1016/j.vascn.2007.01.00310.1016/j.vascn.2007.01.00317391988
- 6. Y. Matsuzawa and A. Lerman, Endothelial dysfunction and coronary artery disease: Assessment, prognosis and treatment, Coron. Art. Dis. 25 (2014) 713–724; https://doi.org/10.1097%2FMCA.000000000000017810.1097/MCA.0000000000000178422030125365643
- 7. M. M. Alem, Endothelial dysfunction in chronic heart failure: assessment, findings, significance, and potential therapeutic targets, Int. J. Mol. Sci.20 (2019) Article ID 3198; https://doi.org/10.3390/ijms2013319810.3390/ijms20133198665153531261886
- 8. M. Endoh, Amrinone, Forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy, Circul. Res. 113 (2013) 358–361; https://doi.org/10.1161/CIRCRESAHA.113.30168910.1161/CIRCRESAHA.113.30168923908328
- 9. S. Steven, K. Frenis, M. Oelze, S. Kalinovic, M. Kuntic, M. T. B. Jimenez, K. Vujacic-Mirski, J. Helm-städter, S. Kröller-Schön, T. Münzel and A. Daiber, Vascular inflammation and oxidative stress: Major triggers for cardiovascular disease, Oxid. Med. Cell. Longev. 2019 (2019) Article ID 7092151 (26 pages); https://doi.org/10.1155/2019/709215110.1155/2019/7092151661239931341533
- 10. J. Habibi, A. R. Aroor, N. A. Das, C. M. Manrique-Acevedo, M. S. Johnson, M. R. Hayden, R. Nistala, C. Wiedmeyer, B. Chandrasekar and V. G. DeMarco, The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat, Cardiovasc. Diabetol. 18 (2019) Article ID 40; https://doi.org/10.1186/s12933-019-0847-810.1186/s12933-019-0847-8643276030909895
- 11. S. Yandrapalli, M. H. Khan, Y. Rochlani and W. S. Aronow, Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy, Ther. Adv. Cardiovasc Dis. 12 (2018) 217–231; 10.1177/175394471878453610.1177/1753944718784536
- 12. P. V. M. Romão, R. A. C. Palozi, L. P. Guarnier, A. O. Silva, B. R. Lorençone, S. R. Nocchi, C. C. de Freitas Sari Moura, E. L. B. Lourenço, D. B. Silva and A. Gasparotto Junior, Cardioprotective effects of Plinia cauliflora (Mart.) Kausel in a rabbit model of doxorubicin-induced heart failure, J. Ethnopharmacol.242 (2019) Article ID 112042; https://doi.org/10.1016/j.jep.2019.11204210.1016/j.jep.2019.112042
- 13. R. K. Trivedi, D. J. Polhemus, Z. Li, D. Yoo, H. Koiwaya, A. Scarborough, T. T. Goodchild and D. J. Lefer, Combined angiotensin receptor–neprilysin inhibitors improve cardiac and vascular function via increased no bioavailability in heart failure, J. Am. Heart Assoc. 7 (2018) e008268; https://doi.org/10.1161/JAHA.117.00826810.1161/JAHA.117.008268
- 14. C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey, M. M. Colvin, M. H. Drazner, G. S. Filippatos, G. C. Fonarow, M. M. Givertz, S. M. Hollenberg, J. Lindenfeld, F. A. Masoudi, P. E. McBride, P. N. Peterson, L. W. Stevenson and C. Westlake, 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, Circulation136 (2017) e137–e161; https://doi.org/10.1161/CIR.000000000000050910.1161/CIR.0000000000000509
- 15. Y. Suematsu, S. Miura, M. Goto, Y. Matsuo, T. Arimura, T. Kuwano, S. Imaizumi, A. Iwata, E. Yahiro and K. Saku, LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice, Eur. J. Heart Fail. 18 (2016) 386–393; https://doi.org/10.1002/ejhf.47410.1002/ejhf.474
- 16. Q.-Y. Zhao, C.-X. Huang, H. Jiang, E. Okello, X. Wang, Y.-H. Tang and G.-S. Li, Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration, Can. J. Cardiol.25 (2009) e115-8; https://doi.org/10.1016/s0828-282x(09)70069-810.1016/S0828-282X(09)70069-8
- 17. J. V. J. McMurray, M. Packer, A. S. Desai, J. Gong, M. P. Lefkowitz, A. R. Rizkala, J. L. Rouleau, V. C. Shi, S. D. Solomon, K. Swedberg and M. R. Zile, Angiotensin-neprilysin inhibition versus enal-april in heart failure, N. Engl. J Med. 371 (2014) 993–1004; https://doi.org/10.1056/NEJMoa140907710.1056/NEJMoa140907725176015
- 18. A. Strigli, C. Raab, S. Hessler, T. Huth, A. J. T. Schuldt, C. Alzheimer, T Friedrich, P. W. Burridge, M. Luedde and M. Schwake, Doxorubicin induces caspase-mediated proteolysis of KV7.1, Commun. Biol. 1 (2018) Article ID 155; https://doi.org/10.1038/s42003-018-0162-z10.1038/s42003-018-0162-z616225830302399
- 19. G. Tse, Mechanisms of cardiac arrhythmias, J. Arrhythm. 32 (2016) 75–81; https://doi.org/10.1016/j.joa.2015.11.00310.1016/j.joa.2015.11.003482358127092186
- 20. J. Zheng, L. H. C. Michelle, M. M. B. Sattar, Y. Huang and J. S. Bian, Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cadiomyocyte injury, Eur. J. Pharmacol. 652 (2011) 82–88; https://doi.org/10.1016/j.ejphar.2010.10.08210.1016/j.ejphar.2010.10.08221114975
- 21. E. K. C. Kong, Y. Huang, J. E. Sanderson, K. B. Chen, S. Yu and C. M. Yu, A novel anti-fibrotic agent, baicalein for the treatment of myocardial fibrosis in spontaneously hypertensive rats, Eur. J. Pharmacol. 658 (2011) 175–181; https://doi.org/10.1016/j.ejphar.2011.02.03310.1016/j.ejphar.2011.02.03321371455
- 22. M. Imran, M. D. Quamrul Hassan, M. D. S. Akhtar, O. Rahman, M. Akhtar and A. K. Najmi, Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats, Clin. Exp. Hypert. 41 (2017) 62–69; https://doi.org/10.1080/10641963.2018.144186210.1080/10641963.2018.144186229595329
- 23. E. De Angelis, M. Pecoraro, M. R. Rusciano, M. Ciccarelli and A. Popolo, Cross-talk between neurohormonal pathways and the immune system in heart failure: A review of the literature, Int. J. Mol. Sci.20 (2019) Article ID 1698; https://doi.org/10.3390/ijms2007169810.3390/ijms20071698648026530959745
- 24. P. M Ridker, E. Danielson, N. Rifai and R. J. Glynn, Valsartan, blood pressure reduction, and C-reactive protein – primary report of the Val-MARC trial, Hypertension48 (2006) 73–79; https://doi.org/10.1161/01.HYP.0000226046.58883.3210.1161/01.HYP.0000226046.58883.3216714425
- 25. S. Toyoda, A. Haruyama, S. Inami, T. Arikawa, F. Saito, R. Watanabe, M. Sakuma, S. Abe, T. Nakajima, A. Tanaka, K. Node and T. Inoue, Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure, J. Cardiol. 75 (2020) 140–147; https://doi.org/10.1016/j.jjcc.2019.07.01110.1016/j.jjcc.2019.07.01131444140
- 26. W. Szczurek and B. S. Jurkiewicz, Oxidative stress and inflammatory markers – the future of heart failure diagnostics?, Kardiochir. Torakochir. Pol.12 (2015) 145–149; https://doi.org/10.5114%2Fkitp.2015.52856
- 27. W. Jing, N. D. Vaziri, A. Nunes, Y. Suematsu, T. Farzaneh, M. Khazaeli and H. Moradi, LCZ696 (sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD, Am. J. Transl. Res. 9 (2017) 5473–5484.